Enact Holdings Inc. Supports Breakthrough T1D’s Project ACT for Transformative T1D Treatments

Breakthrough T1D Launches Initiative to Transform Type 1 Diabetes Treatments

Breakthrough T1D, formerly known as JDRF, unveils its ambitious Project ACT (Accelerate Cell Therapies), aiming to revolutionize the treatment landscape for Type 1 Diabetes (T1D). This initiative is propelled by three substantial gifts totaling $75 million, which will fund the development of stem cell-based islet cell therapies. These therapies hold the promise of enabling individuals with T1D to produce their own insulin, eliminating the need for extensive immunosuppression. This marks a significant departure from traditional treatment modalities, which often entail lifelong management strategies that do not address the underlying autoimmune nature of the disease.

The importance of Project ACT is underscored by the organization’s historical contributions to T1D research and treatment innovations over the past 50 years. Breakthrough T1D has been at the forefront of significant advancements, such as the development of the artificial pancreas and Tzield, the first disease-modifying therapy for T1D. According to CEO Aaron J. Kowalski, Ph.D., the organization's goal is to dismantle existing barriers to access and make cell therapies a viable option for all individuals affected by T1D. By focusing on halting the immune system's assault on insulin-producing beta cells, Breakthrough T1D aims to fundamentally alter the prognosis for those living with this chronic condition.

The launch of Project ACT will be celebrated at the Breakthrough T1D Promise Gala, an event that highlights both the scientific progress made in T1D research and the resilience of those living with the disease. Hosted by Jenna Bush Hager, the gala will also honor Este Haim, a GRAMMY® nominated musician diagnosed with T1D at the age of 14, who will receive the Breakthrough T1D Voice of Influence Award. This recognition spotlights not only the personal narratives linked to T1D but also the community's collective effort toward advancing treatment options. With a focus on technological innovations and a commitment to patient-centered care, Breakthrough T1D positions itself to make significant inroads in the quest for effective therapies that could one day lead to a cure for Type 1 Diabetes.

Investing in Future Solutions

With Project ACT, Breakthrough T1D aligns itself with the latest advancements in regenerative medicine, setting a foundation for groundbreaking research and development in cell therapies. As the community rallies around this initiative, the potential to transform the lives of millions living with T1D comes into sharper focus. This project not only seeks to innovate but also emphasizes the importance of collaboration and support within the T1D ecosystem.

As the organization embarks on this transformative journey, the promise of Project ACT offers hope for a future where T1D is managed more effectively, allowing those affected to lead healthier, more autonomous lives. The ongoing commitment of Breakthrough T1D to tackle the challenges associated with this condition is a crucial step toward redefining the narrative of Type 1 Diabetes.